Results 231 to 240 of about 17,611,247 (302)
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher +12 more
wiley +1 more source
Combination of intermittent fasting and endurance exercise impedes the development of the musculoskeletal system in non-obese growing rats. [PDF]
Wang Z +5 more
europepmc +1 more source
Per‐ and Polyfluoroalkyl Substances and Knee Osteoarthritis: Data From the Osteoarthritis Initiative
Objective To examine whether concentrations of specific per‐ and polyfluoroalkyl substances (PFAS) and a mixture of PFAS relate to incident knee osteoarthritis (KOA) and knee pain progression. Methods Among a case‐cohort sample from the OA Initiative (n = 1,878), we examined associations of serum concentrations of eight PFAS with odds of developing ...
Jeffrey B. Driban +14 more
wiley +1 more source
Editorial: The mechanisms of degenerative and geriatric disorders of the musculoskeletal system. [PDF]
Kuang L.
europepmc +1 more source
Objective Carbamylation, a nonenzymatic post‐translational modification, contributes to rheumatoid arthritis (RA) pathogenesis. Anti‐carbamylated protein antibodies (anti‐CarP) occur in around 50% of patients with RA and associate with greater joint damage. Neutrophil extracellular traps (NETs) are a major source of carbamylated autoantigens. We sought
Shuichiro Nakabo +9 more
wiley +1 more source
The impact of ageing mechanisms on musculoskeletal system diseases in the elderly. [PDF]
Cai Y +12 more
europepmc +1 more source
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis +22 more
wiley +1 more source
Objective Nerve growth factor (NGF), a key mediator of pain, is increased in osteoarthritic (OA) joints. Antibodies against NGF show analgesic effects in painful knee OA, but clinical development was stopped because of side effects in the joints. Knowledge about the biologic effects of NGF on joint tissues is limited. Therefore, we explored the effects
Alia M. Obeidat +14 more
wiley +1 more source
Demystifying Our Knowledge of Stem Cells and Progenitor Cells Part I: Basic Concepts Relevant to the Treatment of Osteonecrosis and Other Diseases of the Musculoskeletal System. [PDF]
Goodman SB, Goodnough LH, Chow SK.
europepmc +1 more source
Objective To assess the 2022 American College of Rheumatology (ACR)/EULAR classification criteria for antineutrophil cytoplasmic antibody–associated vasculitis (AAV) in children with chronic small‐to‐medium vessel vasculitis. Methods A cohort of 574 patients, identified by physician's diagnosis (MD‐diagnosis) in A Registry of Childhood Vasculitis, was ...
David A. Cabral +41 more
wiley +1 more source

